177 related articles for article (PubMed ID: 35798242)
1. Olamkicept(sgp130Fc): The missing trial in Neuromyelitis Optica Spectrum Disorder.
Magro G
Clin Immunol; 2022 Aug; 241():109072. PubMed ID: 35798242
[TBL] [Abstract][Full Text] [Related]
2. Satralizumab might not be enough. Olamkicept (sgp130Fc) in Neuromyelitis Optica Spectrum Disorder.
Magro G
Mult Scler Relat Disord; 2022 Sep; 65():104037. PubMed ID: 35835028
[TBL] [Abstract][Full Text] [Related]
3. Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Fung S; Shirley M
CNS Drugs; 2023 Apr; 37(4):363-370. PubMed ID: 36933107
[TBL] [Abstract][Full Text] [Related]
4. [Local experience of IL-6 pathway inhibition with satralizumab for patients with neuromyelitis optica spectrum disorder].
Prakhova LN; Krasnov VS; Kasatkin DS; Korobko DS
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7. Vyp. 2):68-72. PubMed ID: 35912559
[TBL] [Abstract][Full Text] [Related]
5. Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders.
Paton DM
Drugs Today (Barc); 2021 Mar; 57(3):209-218. PubMed ID: 33729218
[TBL] [Abstract][Full Text] [Related]
6. Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: Implications from immunology, the FcRn pathway and clinical experience.
Sellner J; Sitte HH; Rommer PS
Drug Discov Today; 2021 Jul; 26(7):1591-1601. PubMed ID: 33781948
[TBL] [Abstract][Full Text] [Related]
7. Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options.
Rosso M; Saxena S; Chitnis T
Expert Rev Neurother; 2020 May; 20(5):509-516. PubMed ID: 32306778
[No Abstract] [Full Text] [Related]
8. Satralizumab in the treatment of neuromyelitis optica spectrum disorder.
Duchow A; Bellmann-Strobl J
Neurodegener Dis Manag; 2021 Feb; 11(1):49-59. PubMed ID: 33167776
[TBL] [Abstract][Full Text] [Related]
9. Blockade of IL-6 signaling in neuromyelitis optica.
Araki M
Neurochem Int; 2019 Nov; 130():104315. PubMed ID: 30342072
[TBL] [Abstract][Full Text] [Related]
10. Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment.
Uzawa A; Mori M; Iwai Y; Masuda H; Kuwabara S
Intern Med; 2022 Sep; 61(18):2785-2787. PubMed ID: 35135926
[TBL] [Abstract][Full Text] [Related]
11. Satralizumab for the Treatment of Neuromyelitis Optica Spectrum Disorders.
Gao Y; Zhang B; Yang J
Ann Pharmacother; 2021 Sep; 55(9):1167-1171. PubMed ID: 33246373
[TBL] [Abstract][Full Text] [Related]
12. Review of Satralizumab for Neuromyelitis Optica Spectrum Disorder: A New Biologic Agent Targeting the Interleukin-6 Receptor.
Meher BR; Mohanty RR; Dash A
Cureus; 2024 Feb; 16(2):e55100. PubMed ID: 38558672
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology.
Fujihara K; Bennett JL; de Seze J; Haramura M; Kleiter I; Weinshenker BG; Kang D; Mughal T; Yamamura T
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32820020
[TBL] [Abstract][Full Text] [Related]
14. Severe febrile neutropenia associated with satralizumab in an Argentinian neuromyelitis optica spectrum disorder patient.
Pestchanker C; Diaconchuk M; Lopez P; Montaño MR; Romero W; Zalazar G; Carnero Contentti E
Mult Scler; 2023 Jan; 29(1):150-153. PubMed ID: 36437566
[TBL] [Abstract][Full Text] [Related]
15. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
Carnero Contentti E; Correale J
J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future.
Lin J; Xue B; Li X; Xia J
Int J Neurosci; 2017 Aug; 127(8):735-744. PubMed ID: 27680606
[TBL] [Abstract][Full Text] [Related]
17. Urosepsis Risk in Neuromyelitis Optica Spectrum Disorder Patients Administered Satralizumab.
Fujita R; Aratake Y; Nakata K; Fujii C; Kondo T
Intern Med; 2023 Nov; 62(22):3317-3320. PubMed ID: 37032080
[TBL] [Abstract][Full Text] [Related]
18. Satralizumab: First Approval.
Heo YA
Drugs; 2020 Sep; 80(14):1477-1482. PubMed ID: 32797372
[TBL] [Abstract][Full Text] [Related]
19. Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy.
Lotan I; McGowan R; Levy M
Curr Neuropharmacol; 2021; 19(2):220-232. PubMed ID: 32348222
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 Signaling Blockade Induces Regulatory Plasmablasts in Neuromyelitis Optica Spectrum Disorder.
Akatani R; Chihara N; Hara A; Tsuji A; Koto S; Kobayashi K; Toda T; Matsumoto R
Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200266. PubMed ID: 38889374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
